Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23856034 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL2185848 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL215647 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL9094485 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL6522546 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL27705439 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| Glycerin SCHEMBL27636932 | 0.82 | LMNA (0.36) | LMNAL3MBTL1TDP1 | |
| Valeric Acid SCHEMBL27619472 | 0.82 | AKR1B1 (0.40) | AKR1B1LMNATDP1 | |
| SCHEMBL7642895 | 0.78 | LMNA (0.35) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL27905563 | 0.78 | LMNA (0.35) | AKR1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | SIMON FRASER UNIVERSITY (CA) | 2023-04-27 | — | — | US | disclosed |
| EP-4126897-A1 | METHODS AND REAGENTS FOR SYNTHESIZING NUCLEOSIDES AND ANALOGUES THEREOF | Simon Fraser University (CA) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667280-A | Method and reagent for synthesizing nucleoside and analogue thereof | 西蒙弗雷泽大学 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021191830-A1 | METHODS AND REAGENTS FOR SYNTHESIZING NUCLEOSIDES AND ANALOGUES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2021-09-30 | — | — | WO | disclosed |
| CN-107530369-A | Mononucleotides with bioreversible dithio groups | 索尔斯蒂斯生物有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-106008571-A | Boron-containing small molecules | 安纳考尔医药公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-106008583-A | BORON-CONTAINING SMALL MOLECULES | 安纳考尔医药公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-105949230-A | BORON-CONTAINING SMALL MOLECULES | 安纳考尔医药公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-102532180-B | The little molecule of boracic | 安纳考尔医药公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-102532180-A | Boron-containing small molecules | ANACOR PHARMACEUTICALS INC | 2012-07-04 | — | — | CN | disclosed |
| CN-102348712-A | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | UNIV CARDIFF | 2012-02-08 | — | — | CN | disclosed |
| CN-101505603-A | Boron-containing small molecules | ANACOR PHARMACEUTICALS INC (US) | 2009-08-12 | — | — | CN | disclosed |
| CN-101252839-A | Novel 2 '-C-methyl and 4' -C-methyl nucleoside derivatives | MERCK & CO INC (US) | 2008-08-27 | — | — | CN | disclosed |
| CN-1997377-A | 2' -C-methyl nucleoside derivatives | MERCK & CO INC (US) | 2007-07-11 | — | — | CN | disclosed |
| CN-1315862-C | Methods and compositions for treating flaviviruses and pestiviruses | NOVIRIO PHARMACEUTICALS LTD (VG) | 2007-05-16 | — | — | CN | disclosed |
| CN-1744903-A | Process for the preparation of 2' -branched nucleosides | IDENIX CAYMAN LTD (KY) | 2006-03-08 | — | — | CN | disclosed |
| CN-1468249-A | Methods and compositions for treating flaviviruses and pestiviruses | — | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129710-A1 | Methods and Reagents for Synthesizing Nucleosides and Analogues Thereof | NUDT1, ADAR, APRT | AKR1B1 79/4885LMNA 1420/4885L3MBTL1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.